RankAlpha logo
Back to Rankings

XGN

ExagenC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
+
Peers tracked
9
U.S. public peers
Grade Position
In line
vs peer average
XGN vs peer average
64/100
XGN vs. peer average (C vs. D)
Grade spread
A 1 · B 1 · C 1 · D 1 · F 5
Graded peers loaded
Coverage
9 graded
100% of tracked

Peer overview

CUE is the first available peer comparator.

Cue Biopharma is mainly a therapeutics developer, so it is only a loose small-cap biotech risk-capital comparator rather than a direct peer for diagnostics volume, pricing, or reimbursement execution.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerCUECue Biopharma
XGN
Exagen
CUE
Cue Biopharma
Grade
C
D
Momentum
51
94
Value
41
41
Sentiment
69
0
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Defensive
Open Side-by-Side ComparisonCompare all

Grade position vs CUE

XGN / CUE
Grade Position
In line
XGN vs. peer average (C vs. D)
64/100
Momentum
51
CUE
Value
41
XGN
Sentiment
69
XGN

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs XGN
1
CUE
CUE
D
40/100
+1
2
BDTX
BDTX
A
100/100
-2
3
ONCY
ONCY
F
20/100
+2
4
COYA
Coya Therapeutics Inc Common
F
20/100
+2
5
BNR
Burning Rock Biotech Ltd ADR
F
20/100
+2
CUE is the first peer returned for this comparison set.